Market capitalization | $336.99m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 1.05 |
Dividend yield | 0.00% |
Last dividend (FY23) | $15.12 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-89.73m |
Cash position | $294.94m |
EPS (TTM) EPS | $-2.88 |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
10 Analysts have issued a Talaris Therapeutics Inc forecast:
10 Analysts have issued a Talaris Therapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -90 -90 |
66%
66%
|
Net Profit | -73 -73 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad in 2002 and is headquartered in Louisville, KY.
Head office | United States |
CEO | Sandeep Kulkarni |
Founded | 2021 |
Website | www.tourmalinebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.